TG Therapeutics

The Most Promising Biotech Names Heading Into 2019
The Most Promising Biotech Names Heading Into 2019
Investopedia
biotech
AbbVie
Novavax
Amarin
TG Therapeutics
Flag link:
3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
Motley Fool
TG Therapeutics
Madrigal Pharmaceuticals
Puma Biotechnology
Flag link:
TG stock sinks after setback to blood cancer trial
TG stock sinks after setback to blood cancer trial
Fierce Biotech
TG Therapeutics
FDA
ublituximab-umbralisib
CLL
chronic lymphocytic leukemia
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
TG Therapeutics
Sangamo Therapeutics
Akcea Therapeutics
FDA
Waylivra
umbralisib
SB-913
Flag link:
ASCO 2018 Sends TG Therapeutics Stock Soaring 10% Today
ASCO 2018 Sends TG Therapeutics Stock Soaring 10% Today
Motley Fool
TG Therapeutics
umbralisib
chronic lymphocytic leukemia
ASCO 2018
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Incyte
TG Therapeutics
Cara Therapeutics
CR845
opioids
ublituximab
leukemia
olumiant
rheumatoid arthritis
Flag link:
Data from trials could send these clinical-stage biotech stocks soaring or crashing
Data from trials could send these clinical-stage biotech stocks soaring or crashing
Motley Fool
clinical trials
biotech
Summit Therapeutics
DMD
Jounce Therapeutics
JTX-2011
TG Therapeutics
ublituximab
Flag link:
3 Best Biotech Stocks During Trump's First 100 Days
3 Best Biotech Stocks During Trump's First 100 Days
Motley Fool
biotech stocks
Donald Trump
Esperion Therapeutics
Aurinia Pharmaceuticals
TG Therapeutics
Flag link:
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
TheStreet.com
FDA
drug approvals
Alkermes
ALKS-5461
CytRx
aldoxorubicin
Dynavax Technologies
HEPLISAV-B
Intra-Cellular Therapies
ITI-007
Novan
SB204
Portola Pharmaceuticals
betrixaban
PTC Therapeutics
ataluren
Rigel Pharmaceuticals
fostamatinib
TG Therapeutics
ublituximab
Flag link:
TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK
TG Therapeutics shares rocket up on successful PhIII leukemia study, teeing up a shot at accelerated FDA OK
Endpoints
TG Therapeutics
ublituximab
TG-1101
FDA
CLL
Flag link:
8 Speculative Biotech and Biohealth Stocks With Major Analyst Upside Calls
8 Speculative Biotech and Biohealth Stocks With Major Analyst Upside Calls
24/7 Wall St
GW Pharma
Integra LifeSciences
Minerva Neurosciences
Neurocrine Biosciences
Teladoc
TG Therapeutics
Asterias
Innocoll GmbH
Flag link:
2 Small Biotech Stocks Poised For Substantial Upside
2 Small Biotech Stocks Poised For Substantial Upside
Seeking Alpha
biotech
pSivida
TG Therapeutics
Flag link:
The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers
The Best Performing Biotech Stocks of 2014: Amazing 300% Gainers
24/7 Wall St
Agios Pharmaceuticals
OvaScience
Radius
Prosensa
TG Therapeutics
Bluebird Bio
Receptos
Flag link:
Best and worst 2014 biotech performers on Wall Street
Best and worst 2014 biotech performers on Wall Street
Fierce Biotech
Avanir Pharmaceuticals
Agios Pharmaceuticals
TG Therapeutics
Bluebird Bio
Vivus
Agerion
Theravance
Flag link:
Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-H
Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-H
Yahoo/Globe NewsWire
TGR-1202
chronic lymphocytic leukemia
non-Hodgkin's lymphoma
TG Therapeutics
Flag link:
3 Newsworthy Biotech Stocks: BioDelivery, CytRx, TG Therapeutics
3 Newsworthy Biotech Stocks: BioDelivery, CytRx, TG Therapeutics
Wall St Cheat Sheet
BioDelivery Sciences
TG Therapeutics
CytRx
Flag link:
Tiny Biotech Developing Drugs Akin To Biogen's Rituxan Seen As Potential Buyout Bet
Tiny Biotech Developing Drugs Akin To Biogen's Rituxan Seen As Potential Buyout Bet
Forbes
Biogen Idec
Rituxan
TG Therapeutics
Utuxin
TGR-1202
CLL
chronic lymphocytic leukemia
non-Hodgkin's lymphoma
Flag link:
TG Therapeutic: A Small-Cap Biotech With Great Potential Growth
TG Therapeutic: A Small-Cap Biotech With Great Potential Growth
Seeking Alpha
TG Therapeutics
Flag link:
Don't Be Surprised If Underpriced Small-Cap Biotechs Catch Investors' Eye Once Again
Don't Be Surprised If Underpriced Small-Cap Biotechs Catch Investors' Eye Once Again
Forbes
Coronado Biosciences
TG Therapeutics
Pharmacyclics
Flag link: